BRPI1005919A2 - composição imunogênica - Google Patents

composição imunogênica

Info

Publication number
BRPI1005919A2
BRPI1005919A2 BRPI1005919A BRPI1005919A BRPI1005919A2 BR PI1005919 A2 BRPI1005919 A2 BR PI1005919A2 BR PI1005919 A BRPI1005919 A BR PI1005919A BR PI1005919 A BRPI1005919 A BR PI1005919A BR PI1005919 A2 BRPI1005919 A2 BR PI1005919A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
BRPI1005919A
Other languages
English (en)
Inventor
Nobuo Ida
Reiji Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI1005919A2 publication Critical patent/BRPI1005919A2/pt
Publication of BRPI1005919B1 publication Critical patent/BRPI1005919B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025Nucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1005919-9A 2009-02-27 2010-02-26 Composição imunogênica BRPI1005919B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009045555 2009-02-27
JP2009-045555 2009-02-27
PCT/JP2010/053055 WO2010098432A1 (ja) 2009-02-27 2010-02-26 免疫原性組成物

Publications (2)

Publication Number Publication Date
BRPI1005919A2 true BRPI1005919A2 (pt) 2016-02-10
BRPI1005919B1 BRPI1005919B1 (pt) 2021-06-22

Family

ID=42665636

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005919-9A BRPI1005919B1 (pt) 2009-02-27 2010-02-26 Composição imunogênica

Country Status (15)

Country Link
US (1) US9056095B2 (pt)
EP (1) EP2402032B1 (pt)
JP (1) JP6008345B2 (pt)
KR (1) KR20110128284A (pt)
CN (1) CN102333541B (pt)
AU (1) AU2010218752B2 (pt)
BR (1) BRPI1005919B1 (pt)
CA (1) CA2753567C (pt)
DK (1) DK2402032T3 (pt)
ES (1) ES2755361T3 (pt)
HU (1) HUE046865T2 (pt)
MX (1) MX2011008923A (pt)
PL (1) PL2402032T3 (pt)
PT (1) PT2402032T (pt)
WO (1) WO2010098432A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
ES2829819T3 (es) * 2010-08-26 2021-06-02 Toray Industries Composición inmunogénica
JPWO2013085021A1 (ja) * 2011-12-09 2015-04-27 株式会社林原 抗体産生増強用の組成物
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
CN102988981B (zh) * 2012-12-13 2015-03-04 中国水产科学研究院黄海水产研究所 一种增强爱德华氏菌疫苗免疫接种效果的佐剂及使用方法
UA130246C2 (uk) 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
RU2702987C2 (ru) * 2013-10-09 2019-10-15 Торэй Индастриз, Инк. Иммуностимулятор
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
US20150297706A1 (en) * 2014-04-18 2015-10-22 Auburn University Particulate Vaccine Formulations for Inducing Innate and Adaptive Immunity
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
GB201918963D0 (en) 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
WO2023032892A1 (ja) 2021-08-30 2023-03-09 東レ株式会社 免疫原性増強用組成物
CN117813112A (zh) 2021-08-30 2024-04-02 东丽株式会社 免疫原性增强用组合物
CA3232439A1 (en) 2021-09-16 2023-03-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
CA2600085A1 (en) 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
JP2008088158A (ja) 2006-09-05 2008-04-17 Toray Ind Inc 親水性活性物質含有微粒子の製造方法
JP2008254338A (ja) 2007-04-05 2008-10-23 Bridgestone Corp タイヤの製造方法およびその装置
CN102227445B (zh) 2008-09-30 2014-12-17 东丽株式会社 结合丙型肝炎病毒的包膜蛋白2的抗体以及利用所述抗体鉴定丙型肝炎病毒的基因型的方法

Also Published As

Publication number Publication date
DK2402032T3 (da) 2019-11-04
BRPI1005919B1 (pt) 2021-06-22
JP6008345B2 (ja) 2016-10-19
CN102333541B (zh) 2014-09-03
CA2753567C (en) 2019-12-31
ES2755361T3 (es) 2020-04-22
PT2402032T (pt) 2019-11-19
AU2010218752A1 (en) 2011-08-25
KR20110128284A (ko) 2011-11-29
US20110300223A1 (en) 2011-12-08
AU2010218752B2 (en) 2015-05-28
WO2010098432A1 (ja) 2010-09-02
EP2402032A4 (en) 2013-05-01
JPWO2010098432A1 (ja) 2012-09-06
CA2753567A1 (en) 2010-09-02
CN102333541A (zh) 2012-01-25
MX2011008923A (es) 2011-09-09
EP2402032B1 (en) 2019-08-14
EP2402032A1 (en) 2012-01-04
PL2402032T3 (pl) 2020-03-31
HUE046865T2 (hu) 2020-03-30
US9056095B2 (en) 2015-06-16

Similar Documents

Publication Publication Date Title
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
BRPI1015474A2 (pt) composição
HRP20181347T1 (hr) Formulacije dvoslojne tablete
UY33161A (es) Composiciones plaguicidas
LT3431076T (lt) Patobulinta lipidinė kompozicija
DK3097925T3 (da) Farmaceutisk sammensætning
DOP2011000396A (es) Composiciones novedosas
BRPI1004940A2 (pt) composição farmacêutica
BRPI1010301A2 (pt) composição.
GB0913681D0 (en) Immunogenic composition
BRPI1005919A2 (pt) composição imunogênica
EP2488586A4 (en) HARDENING COMPOSITION
BRPI1010690A2 (pt) composições
EP2495286A4 (en) HARDENING COMPOSITION
BRPI1009465A2 (pt) Formulação
BRPI1015939A2 (pt) composição farmacêutica
EP2515938A4 (en) IMMUNOGENIC COMPOSITIONS
EP3348251C0 (en) SUN PROTECTION COMPOSITIONS
SI2635269T1 (sl) Kombinacijski sestavek
EP2609931A4 (en) IMMUNOGENIC COMPOSITION
BRPI1005318A2 (pt) composição
SMT202100150T1 (it) Formulazioni migliorate

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/39 (2006.01), A61K 47/60 (2017.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09X Decision of grant: republication
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.